...
首页> 外文期刊>European respiratory review >Epoprostenol and pulmonary arterial hypertension: 20xe2x80x85years of clinical experience
【24h】

Epoprostenol and pulmonary arterial hypertension: 20xe2x80x85years of clinical experience

机译:依泊汀和肺动脉高压:20xe2x80x85年的临床经验

获取原文
           

摘要

Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20xe2x80x85years since the introduction of this prostacyclin analogue; the outlook for patients with PAH has improved; with survival rates now double those from the era before the development of disease-specific treatments. Today; there are a large amount of data on the clinical role of prostacyclin treatments and a body of evidence attesting the efficacy of epoprostenol in improving exercise capacity; key haemodynamic parameters and PAH symptoms; as well as in reducing mortality. The place of epoprostenol in the therapeutic management of PAH continues to evolve; with the development of new formulations and use in combination with other drug classes. In this review; we provide a historical perspective on the first 20xe2x80x85years of epoprostenol; a therapy that led to evidence-based study of PAH-specific treatments and the subsequent expansion of treatment options for PAH.
机译:依泊烯醇是第一个被批准用于治疗肺动脉高压(PAH)的疗法。自从引入前列环素类似物以来的20xe2x80x85年; PAH患者的前景有所改善;现在的存活率是疾病特定疗法之前的两倍。今天;有大量关于前列环素治疗的临床作用的数据,有大量证据证明依普西汀在改善运动能力方面的功效;关键的血液动力学参数和PAH症状;以及降低死亡率。依前列烯醇在多环芳烃的治疗中的地位不断发展。随着新配方的开发以及与其他药物类别的组合使用。在这篇评论中;我们提供了前20年ex2x80x85年的依泊烯醇的历史观点;该疗法导致对PAH特定疗法进行循证研究,并随后扩展了PAH的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号